Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment PharmaTimesStudy expands development of the antibody into hepatocellular carcinomaClinical DataOncologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Study expands development of the antibody into hepatocellular carcinoma Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to EuropeNext: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
